

# BÖLÜM 20

## TÜKRÜK BEZİ MALIGN NEOPLAZMLARI



Ethem İLHAN<sup>1</sup>

### GİRİŞ

Tükrük bezi tümörleri, histolojileri ve biyolojik davranışları bakımından önemli ölçüde farklılık gösteren, nadir görülen, heterojen lezyonlardır (1). Tükrük bezi tümörleri bütün baş boyun tümörlerinin %3-6'sını oluşturur (2-5).

Parotis bezi anatomik olarak tükrük bezi tümörlerinin en sık görüldüğü bölgedir ve tüm tükrük bezi tümörlerinin yüzde 80-85'i buradan kaynaklanır (1, 6). Parotis bezi kaynaklı tümörlerin yaklaşık %75'i benign ve % 25'i maligndir (3).

Tükrük bezi tümörleri daha az sıklıkla submandibular, sublingual ve ağız, üst solunum yolu ve aerodigestif bölgede yer alan minör tükrük bezlerinden kaynaklanır (6). Parotis bezinden kaynaklanan tümörlerin aksine, submandibular bez tümörlerinin %40-45'i, sublingual bez tümörlerinin %70-90'ı ve minör tükrük bezi tümörlerinin %50-75'i malign karakterdedir.

Histolojik olarak en sık görülen benign tükrük bezi tümörü, tüm tükrük bezi tümörlerinin de yaklaşık yarısını oluşturan pleomorfik adenomdur.

En sık görülen malign tükrük bezi tümörleri, birlikte tüm malign tükrük bezi tümörlerinin yaklaşık yarısını oluşturan mukoepidermoid karsinom ve adenoid kistik karsinomdur (7-9).

<sup>1</sup> Op. Dr., İstanbul Gaziosmanpaşa Eğitim ve Araştırma Hastanesi, Kulak Burun ve Boğaz Hastalıkları Kliniği, ethemilhan@yahoo.com



## KAYNAKLAR

1. El-Naggar AK, Chan JKC, Takata T, et al. The fourth edition of the head and neck World Health Organization blue book: editors' perspectives. *Hum Pathol.* 2017;66:10-12.
2. Bradley PJ. Classification of Salivary Gland Neoplasms. *Adv Otorhinolaryngol.* 2016;78:1-8.
3. Griffith CC, Schmitt AC, Little JL, et al. New developments in salivary gland pathology: clinically useful ancillary testing and new potentially targetable molecular alterations. *Archives of pathology & laboratory medicine.* 2017;141 (3):381-395.
4. Sood S, McGurk M, Vaz F. Management of salivary gland tumours: United Kingdom national multidisciplinary guidelines. *The Journal of Laryngology & Otology.* 2016;130 (S2):S142-S149.
5. Speight P, Barrett A. Salivary gland tumours. *Oral diseases.* 2002;8 (5):229-240.
6. Guzzo M, Locati LD, Prott FJ, et al. Major and minor salivary gland tumors. *Crit Rev Oncol Hematol.* 2010;74 (2):134-148.
7. Dillon PM, Chakraborty S, Moskaluk CA, et al. Adenoid cystic carcinoma: a review of recent advances, molecular targets, and clinical trials. *Head & neck.* 2016;38 (4):620-627.
8. Hay AJ, Migliacci J, Karassawa Zanon D, et al. Minor salivary gland tumors of the head and neck—memorial Sloan Kettering experience: Incidence and outcomes by site and histological type. *Cancer.* 2019;125 (19):3354-3366.
9. Xiao CC, Zhan KY, White-Gilbertson SJ, et al. Predictors of nodal metastasis in parotid malignancies: a national cancer data base study of 22,653 patients. *Otolaryngology--Head and Neck Surgery.* 2016;154 (1):121-130.
10. Jayaprakash V, Merzianu M, Warren GW, et al. Survival rates and prognostic factors for infiltrating salivary duct carcinoma: analysis of 228 cases from the Surveillance, Epidemiology, and End Results database. *Head & neck.* 2014;36 (5):694-701.
11. O'Brien CJ, And VBM, Mijailovic M. Evaluation of 242 consecutive parotidectomies performed for benign and malignant disease. *Australian and New Zealand Journal of Surgery.* 1993;63 (11):870-877.
12. Bradley PJ, McGurk M. Incidence of salivary gland neoplasms in a defined UK population. *British Journal of Oral and Maxillofacial Surgery.* 2013;51 (5):399-403.
13. Merrick Y, Albeck H, Nielsen NH, et al. Familial clustering of salivary gland carcinoma in Greenland. *Cancer.* 1986;57 (10):2097-2102.
14. Arslanoğlu S. Tükürük bezi tümörleri: Epidemiyoloji, sınıflaması ve klinik özellikleri. *Türkiye klinikleri kulak burun boğaz özel konular.* 2021;1 (1):1-4.
15. Sentani K, Ogawa I, Ozasa K, et al. Characteristics of 5015 Salivary Gland Neoplasms Registered in the Hiroshima Tumor Tissue Registry over a Period of 39 Years. *J Clin Med.* 2019;8 (5).
16. Spiro RH. Salivary neoplasms: overview of a 35-year experience with 2,807 patients. *Head & neck surgery.* 1986;8 (3):177-184.
17. Saku T, Hayashi Y, Takahara O, et al. Salivary gland tumors among atomic bomb survivors, 1950-1987. *Cancer.* 1997;79 (8):1465-1475.
18. Boukheris H, Ron E, Dores GM, et al. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. *Cancer.* 2008;113 (11):3153-3159.
19. Boukheris H, Stovall M, Gilbert ES, et al. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. *Int J Radiat Oncol Biol Phys.* 2013;85 (3):776-783.
20. Chowdhry AK, McHugh C, Fung C, et al. Second primary head and neck cancer after Hodgkin lymphoma: a population-based study of 44,879 survivors of Hodgkin lymphoma. *Cancer.* 2015;121 (9):1436-1445.



21. Schneider AB, Lubin J, Ron E, et al. Salivary gland tumors after childhood radiation treatment for benign conditions of the head and neck: dose-response relationships. *Radiat Res.* 1998;149 (6):625-630.
22. Horn-Ross PL, Ljung BM, Morrow M. Environmental factors and the risk of salivary gland cancer. *Epidemiology.* 1997;8 (4):414-419.
23. de Ru JA, Plantinga RF, Major MH, et al. Warthin's tumour and smoking. *B-ent.* 2005;1 (2):63-66.
24. Pinkston JA, Cole P. Cigarette smoking and Warthin's tumor. *Am J Epidemiol.* 1996;144 (2):183-187.
25. Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. *Aids.* 2000;14 (5):553-559.
26. Shebl FM, Bhatia K, Engels EA. Salivary gland and nasopharyngeal cancers in individuals with acquired immunodeficiency syndrome in United States. *Int J Cancer.* 2010;126 (10):2503-2508.
27. Hafed L, Farag H, Shaker O, et al. Is human papilloma virus associated with salivary gland neoplasms? An in situ-hybridization study. *Arch Oral Biol.* 2012;57 (9):1194-1199.
28. Skálová A, Kašpírková J, Andrlé P, et al. Human papillomaviruses are not involved in the etiopathogenesis of salivary gland tumors. *Cesk Patol.* 2013;49 (2):72-75.
29. Swanson GM, Burns PB. Cancers of the salivary gland: workplace risks among women and men. *Ann Epidemiol.* 1997;7 (6):369-374.
30. Bradley PJ. Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms. *Adv Otorhinolaryngol.* 2016;78:9-16.
31. Stodulski D, Mikaszewski B, Stankiewicz C. Signs and symptoms of parotid gland carcinoma and their prognostic value. *International journal of oral and maxillofacial surgery.* 2012;41 (7):801-806.
32. Lee WH, Tseng TM, Hsu HT, et al. Salivary gland tumors: A 20-year review of clinical diagnostic accuracy at a single center. *Oncology letters.* 2014;7 (2):583-587.
33. McKean M, Lee K, McGregor I. The distribution of lymph nodes in and around the parotid gland: an anatomical study. *British journal of plastic surgery.* 1985;38 (1):1-5.
34. Diercks GR, Rosow DE, Prasad M, et al. A Case of preoperative "first-bite syndrome" associated with mucoepidermoid carcinoma of the parotid gland. *The Laryngoscope.* 2011;121 (4):760-762.
35. Zhan KY, Khaja SF, Flack AB, et al. Benign parotid tumors. *Otolaryngologic Clinics of North America.* 2016;49 (2):327-342.
36. Eneroth CM. Facial nerve paralysis. A criterion of malignancy in parotid tumors. *Arch Otolaryngol.* 1972;95 (4):300-304.
37. Witt RL. Major salivary gland cancer. *Surg Oncol Clin N Am.* 2004;13 (1):113-127.
38. Davud B, Sirjani JSLJ, Beth M, Beadle, John B, Sunwoo. Malignant Neoplasms of the Salivary Glands. In: Flint PW FH, Haughey BH, Lesperance MM, Lund VJ, Robbins KT, Thomas JR, editor. Cummings Otolaryngology. 2. 7 ed. Philadelphia: Elsevier; 2020. p. 1189-1212.
39. Lombardi D, Accorona R, Lambert A, et al. Long-term outcomes and prognosis in submandibular gland malignant tumors: A multicenter study. *Laryngoscope.* 2018;128 (12):2745-2750.
40. Bhattacharyya N. Survival and prognosis for cancer of the submandibular gland. *J Oral Maxillofac Surg.* 2004;62 (4):427-430.
41. Zdanowski R, Dias FL, Barbosa MM, et al. Sublingual gland tumors: clinical, pathologic, and therapeutic analysis of 13 patients treated in a single institution. *Head Neck.* 2011;33 (4):476-481.
42. Vander Poorten VL, Balm AJ, Hilgers FJ, et al. Stage as major long term outcome predictor in minor salivary gland carcinoma. *Cancer.* 2000;89 (6):1195-1204.



43. Pires FR, Pringle GA, de Almeida OP, et al. Intra-oral minor salivary gland tumors: a clinicopathological study of 546 cases. *Oral Oncol.* 2007;43 (5):463-470.
44. Strick MJ, Kelly C, Soames JV, et al. Malignant tumours of the minor salivary glands--a 20 year review. *Br J Plast Surg.* 2004;57 (7):624-631.
45. Eneroth CM, Franzén S, Zajicek J. Aspiration biopsy of salivary gland tumors. A critical review of 910 biopsies. *Acta Cytol.* 1967;11 (6):470-472.
46. Engzell U, Esposti PL, Rubio C, et al. Investigation on tumour spread in connection with aspiration biopsy. *Acta Radiol Ther Phys Biol.* 1971;10 (4):385-398.
47. Castle JT, Thompson LD, Frommelt RA, et al. Polymorphous low grade adenocarcinoma: a clinicopathologic study of 164 cases. *Cancer.* 1999;86 (2):207-219.
48. Saveria AT, Sloman A, Huvos AG, et al. Myoepithelial carcinoma of the salivary glands: a clinicopathologic study of 25 patients. *Am J Surg Pathol.* 2000;24 (6):761-774.
49. Fakhry N, Santini L, Lagier A, et al. Fine needle aspiration cytology and frozen section in the diagnosis of malignant parotid tumours. *Int J Oral Maxillofac Surg.* 2014;43 (7):802-805.
50. Witt BL, Schmidt RL. Ultrasound-guided core needle biopsy of salivary gland lesions: a systematic review and meta-analysis. *Laryngoscope.* 2014;124 (3):695-700.
51. Pusztaszeri M, Baloch Z, Vielh P, et al. Application of the Milan system for reporting risk stratification in salivary gland cytopathology. *Cancer Cytopathol.* 2018;126 (1):69-70.
52. Bano C, Tekeli K, Smith J, et al. Biopsy techniques for parotid neoplasms. *HONG KONG JOURNAL OF RADIOLOGY.* 2018;21 (2):94-98.
53. Shah KS, Ethunandan M. Tumour seeding after fine-needle aspiration and core biopsy of the head and neck-a systematic review. *British Journal of Oral and Maxillofacial Surgery.* 2016;54 (3):260-265.
54. Seethala RR, LiVolsi VA, Baloch ZW. Relative accuracy of fine-needle aspiration and frozen section in the diagnosis of lesions of the parotid gland. *Head Neck.* 2005;27 (3):217-223.
55. Koischwitz D, Gritzmann N. Ultrasound of the neck. *Radiol Clin North Am.* 2000;38 (5):1029-1045.
56. Kotecha S, Bhatia P, Rout PG. Diagnostic ultrasound in the head and neck region. *Dent Update.* 2008;35 (8):529-530, 533-524.
57. Freling NJ, Molenaar WM, Vermey A, et al. Malignant parotid tumors: clinical use of MR imaging and histologic correlation. *Radiology.* 1992;185 (3):691-696.
58. Som PM, Biller HF. High-grade malignancies of the parotid gland: identification with MR imaging. *Radiology.* 1989;173 (3):823-826.
59. Stahl A, Dzewas B, Schwaiger M, et al. Excretion of FDG into saliva and its significance for PET imaging. *Nuklearmedizin.* 2002;41 (5):214-216.
60. Lydiatt WM MS, O'Sullivan B. Malor Salivary Glands. In: MB A, editor. *AJCC Cancer Staging Manual.* 8 ed. New York: springer; 2017. p. 95.
61. Helmus C. Subtotal parotidectomy: a 10-year review (1985 to 1994). *Laryngoscope.* 1997;107 (8):1024-1027.
62. Lim YC, Lee SY, Kim K, et al. Conservative parotidectomy for the treatment of parotid cancers. *Oral oncology.* 2005;41 (10):1021-1027.
63. Guntinas-Lichius O, Klussmann JP, Schroeder U, et al. Primary parotid malignoma surgery in patients with normal preoperative facial nerve function: outcome and long-term postoperative facial nerve function. *Laryngoscope.* 2004;114 (5):949-956.
64. Sullivan MJ, Breslin K, McClatchey KD, et al. Malignant parotid gland tumors: a retrospective study. *Otolaryngol Head Neck Surg.* 1987;97 (6):529-533.



65. Kimata Y, Sakuraba M, Hishinuma S, et al. Free vascularized nerve grafting for immediate facial nerve reconstruction. *Laryngoscope*. 2005;115 (2):331-336.
66. Eisele DW, Johns ME. Salivary gland neoplasms: Karger; 2016.
67. Meier JD, Wenig BL, Manders EC, et al. Continuous intraoperative facial nerve monitoring in predicting postoperative injury during parotidectomy. *Laryngoscope*. 2006;116 (9):1569-1572.
68. Eisele DW, Wang SJ, Orloff LA. Electrophysiologic facial nerve monitoring during parotidectomy. *Head Neck*. 2010;32 (3):399-405.
69. Nouraei SA, Ismail Y, Ferguson MS, et al. Analysis of complications following surgical treatment of benign parotid disease. *ANZ J Surg*. 2008;78 (3):134-138.
70. Scianna JM, Petruzzelli GJ. Contemporary management of tumors of the salivary glands. *Curr Oncol Rep*. 2007;9 (2):134-138.
71. de Bree R, Duyndam JE, Kuik DJ, et al. Repeated botulinum toxin type A injections to treat patients with Frey syndrome. *Arch Otolaryngol Head Neck Surg*. 2009;135 (3):287-290.
72. Linkov G, Morris LG, Shah JP, et al. First bite syndrome: incidence, risk factors, treatment, and outcomes. *Laryngoscope*. 2012;122 (8):1773-1778.
73. Rinaldo A, Shaha AR, Pellitteri PK, et al. Management of malignant sublingual salivary gland tumors. *Oral Oncol*. 2004;40 (1):2-5.
74. Cianchetti M, Sandow PS, Scarborough LD, et al. Radiation therapy for minor salivary gland carcinoma. *Laryngoscope*. 2009;119 (7):1334-1338.
75. Parsons JT, Mendenhall WM, Stringer SP, et al. Management of minor salivary gland carcinomas. *Int J Radiat Oncol Biol Phys*. 1996;35 (3):443-454.
76. Armstrong JG, Harrison LB, Thaler HT, et al. The indications for elective treatment of the neck in cancer of the major salivary glands. *Cancer*. 1992;69 (3):615-619.
77. Bell RB, Dierks EJ, Homer L, et al. Management and outcome of patients with malignant salivary gland tumors. *J Oral Maxillofac Surg*. 2005;63 (7):917-928.
78. Kelley DJ, Spiro RH. Management of the neck in parotid carcinoma. *Am J Surg*. 1996;172 (6):695-697.
79. Stennert E, Kisner D, Jungehulsing M, et al. High incidence of lymph node metastasis in major salivary gland cancer. *Arch Otolaryngol Head Neck Surg*. 2003;129 (7):720-723.
80. Terhaard CH, Lubsen H, Rasch CR, et al. The role of radiotherapy in the treatment of malignant salivary gland tumors. *Int J Radiat Oncol Biol Phys*. 2005;61 (1):103-111.
81. Zbären P, Schüpbach J, Nuyens M, et al. Elective neck dissection versus observation in primary parotid carcinoma. *Otolaryngol Head Neck Surg*. 2005;132 (3):387-391.
82. Amini A, Waxweiler TV, Brower JV, et al. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma: Data From the National Cancer Data Base. *JAMA Otolaryngol Head Neck Surg*. 2016;142 (11):1100-1110.
83. Gao M, Hao Y, Huang MX, et al. Clinicopathological study of distant metastases of salivary adenoid cystic carcinoma. *Int J Oral Maxillofac Surg*. 2013;42 (8):923-928.
84. Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. *Laryngoscope*. 2001;111 (8):1434-1439.
85. Gutschenritter T, Machiorlatti M, Vesely S, et al. Outcomes and Prognostic Factors of Resected Salivary Gland Malignancies: Examining a Single Institution's 12-year Experience. *Anticancer Res*. 2017;37 (9):5019-5025.